A Rare-Disease Biotech CEO Steps In at $2.14
Prashant Kohli runs Grace Therapeutics, a company chasing treatments for rare and orphan diseases like aneurysmal brain hemorrhage, and he just put $214,000 into his own stock at $2.14. This is his first buy here, and he's the second insider in a month to step in, so a small cluster is forming. The tape is the problem. Every timeframe reads sell, and healthcare is getting sold off broadly right now, so the CEO is buying into a downtrend. One thing to watch: price is sitting right on the 8-day at $2.14 with the 8 and 20 converging, so if it crosses up the algorithms could join fast. Until that happens, this is a name to track, not chase.
The Filing
| Ticker | GRCE |
| Company | Grace Therapeutics, Inc. |
| Insider | Prashant Kohli, Chief Executive Officer |
| Buy amount | $214,000 |
| Filing date | September 10, 2026 |
| Conviction | Favorable · 66/100 |
| Setup type | Accumulation |
Ultimate members received this analysis in real time.